Gu Ruxin, Huang Ying, Li Yin, Zhu Tong, Ma Chao, Tao Gaojian
Department of Pain Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, People's Republic of China.
J Pain Res. 2025 Aug 7;18:3933-3942. doi: 10.2147/JPR.S532000. eCollection 2025.
Chronic postoperative abdominal pain (CPAP) manifests as neuropathic or mixed pain, and conservative treatments often only provide temporary relief. This study evaluated the efficacy and safety of combining dorsal root ganglion pulsed radiofrequency (DRG-PRF) with scar radiofrequency ablation (RFA) for a better treatment.
A total of 48 CPAP patients were divided into the scar RFA group (RFA group, n = 25) and the combination of DRG-PRF and scar RFA group (RFA+PRF group, n = 23). The visual analogue scale (VAS) and Globe Pain Scale (GPS) questionnaires were used for pain intensity and its effects before and at intervals of 1, 7, 30, 90 and 180 days after the procedure.
Baseline scores were comparable. The RFA+PRF group demonstrated significantly lower VAS scores at 1-day (1.2 ± 1.0 vs 1.6 ± 1.1, = 0.040), 30-day (2.3 ± 1.1 vs 3.0 ± 0.9, < 0.001), 90-day (2.7 ± 1.3 vs 3.7 ± 1.3, < 0.001), 180-day of follow-up (2.7 ± 1.1 vs 3.5 ± 1.0, = 0.002). GPS scores also showed significantly greater improvement in the RFA+PRF group at 30-day (51.2 ± 15.5 vs 62.2 ± 15.3, = 0.028), 90-day (67.4 ± 16.3 vs 85.3 ± 14.7, = 0.004), and 180-day (48.4 ± 13.3 vs 62.6 ± 10.9, = 0.011) post-procedure. Additionally, a significantly higher proportion of patients in the RFA+PRF group achieved ≥50% pain relief at both 3 and 6 months ( < 0.05). No adverse reactions were observed in any participants.
The combination of DRG-PRF and scar RFA has demonstrated significant efficacy and high safety in the treatment of CPAP. Compared to scar RFA alone, the combined therapy provides more durable and significant long-term pain relief, making it a better choice for pain management in CPAP patients.
慢性术后腹痛(CPAP)表现为神经性疼痛或混合性疼痛,保守治疗往往只能提供暂时缓解。本研究评估了将背根神经节脉冲射频(DRG-PRF)与瘢痕射频消融(RFA)相结合以获得更好治疗效果的有效性和安全性。
总共48例CPAP患者被分为瘢痕RFA组(RFA组,n = 25)和DRG-PRF与瘢痕RFA联合组(RFA+PRF组,n = 23)。使用视觉模拟量表(VAS)和全球疼痛量表(GPS)问卷来评估术前以及术后1、7、30、90和180天的疼痛强度及其影响。
基线评分具有可比性。RFA+PRF组在术后1天(1.2±1.0 vs 1.6±1.1,P = 0.040)、30天(2.3±1.1 vs 3.0±0.9,P<0.001)、90天(2.7±1.3 vs 3.7±1.3,P<0.001)、180天随访时(2.7±1.1 vs 3.5±1.0,P = 0.002)的VAS评分显著更低。GPS评分在术后30天(51.2±15.5 vs 62.2±15.3,P = 0.028)、90天(67.4± 16.3 vs 85.3±14.7,P = 0.004)和180天(48.4±13.3 vs 62.6±10.9,P = 0. 011)时,RFA+PRF组也显示出显著更大的改善。此外,RFA+PRF组在3个月和6个月时疼痛缓解≥50%的患者比例显著更高(P<0.05)。未观察到任何参与者出现不良反应。
DRG-PRF与瘢痕RFA联合治疗在CPAP治疗中显示出显著疗效和高安全性。与单独的瘢痕RFA相比,联合治疗提供了更持久、更显著的长期疼痛缓解,使其成为CPAP患者疼痛管理的更好选择。